Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Broadening inclusion of vulnerable populations in HIV vaccine trials.

Lau CY, Cardinali M, Sato PA, Fix A, Flores J.

Expert Rev Vaccines. 2008 Mar;7(2):259-68. doi: 10.1586/14760584.7.2.259. Review.

PMID:
18324894
2.

HIV vaccine development and clinical trials.

Hoff R, McNamara J, Fowler M, McCauley M.

Acta Paediatr Suppl. 1994 Aug;400:73-7. Review.

PMID:
7833567
3.

Cultural feasibility studies in preparation for clinical trials to reduce maternal-infant HIV transmission in Haiti.

Coreil J, Losikoff P, Pincu R, Mayard G, Ruff AJ, Hausler HP, Desormeau J, Davis H, Boulos R, Halsey NA.

AIDS Educ Prev. 1998 Feb;10(1):46-62.

PMID:
9505098
5.

The role of prevention research in HIV vaccine trials.

Vermund SH.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S303-5.

PMID:
7865326
6.

Conference on advances in AIDS vaccine development--1993. Report of Perinatal Intervention Working Group.

McNamara JG, Rogers M, Goldenthal K, Jackson JB, Rossi P, Fenton T, Fast PE.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S161-4. No abstract available.

PMID:
7865292
7.

Challenges to conducting HIV preventative vaccine trials with adolescents.

McClure CA, Gray G, Rybczyk GK, Wright PF.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):726-33. Review.

PMID:
15167292
8.

Phase I AIDS vaccine trial in infants begins in Uganda.

Kresge KJ.

IAVI Rep. 2006 Sep-Oct;10(5):16. No abstract available.

9.

[BCG vaccination and development of an innovative vaccine for preventing vertical HIV transmission in Africa].

Pontrelli G, Colizzi V.

Ig Sanita Pubbl. 2006 Mar-Apr;62(2):189-99. Review. Italian.

PMID:
17206189
10.

Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.

Amirfar S, Hollenberg JP, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):219-25.

PMID:
16951648
11.

Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.

Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, Khanani F, Emrick CB, MacQueen KM.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):63-71.

PMID:
11176270
12.

An HIV vaccine: how and when?

Esparza J.

Bull World Health Organ. 2001;79(12):1133-7.

13.

AIDS vaccine: efficacy, safety and ethics.

Veljkovic V, Veljkovic N, Glisic S, Ho MW.

Vaccine. 2008 Jun 6;26(24):3072-7. doi: 10.1016/j.vaccine.2007.11.061. Epub 2007 Dec 17.

PMID:
18164521
14.

A safe, effective and affordable HIV vaccine--an urgent global need.

Joseph J, Etcheverry F, Alcami J, MarĂ­a GJ.

AIDS Rev. 2005 Jul-Sep;7(3):131-8. Review.

PMID:
16302460
15.

Therapeutic vaccine trails in Thailand.

Churdboonchart V.

J HIV Ther. 2004 Sep;9(3):57-9. Review.

PMID:
15534562
17.

Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.

Ammann AJ.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):509-12. doi: 10.1097/QAI.0b013e3181aa8a3d. Review. No abstract available.

PMID:
19521253
18.
19.

HIV vaccine efficacy trials: A brief history, and options for going forward.

McKinnon LR, Card CM; CIHR International Infectious Diseases and Global Health Training Program (IID&GHTP).

AIDS Rev. 2010 Oct-Dec;12(4):209-17. Review.

PMID:
21179185
20.

Pathogenesis of HIV disease: opportunities for new prevention interventions.

Fauci AS.

Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S206-12. doi: 10.1086/522540.

PMID:
18190288

Supplemental Content

Support Center